Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 383 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma March 16, 2026 Choosing to act on cancer: Our Manifesto for Cancer Research and... April 20, 2023 120 years of Cancer Research UK: how science transformed survival rates December 19, 2022 At 27, She Was Told She Was Too Young For Breast... February 6, 2020 Load more HOT NEWS Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... Research with Integrity – integrating training into research culture Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for...
